Pyramax (pyronaridine-artesunate)

About Shinpoong Pharm

Shinpoong Pharm is a public South Korean pharmaceutical company with a strategic focus on anti-infectives, especially for malaria and neglected tropical diseases. Its flagship product, Pyramax, is a WHO-prequalified artemisinin-based combination therapy (ACT) for malaria, representing a significant commercial and public health achievement. The company is expanding its pipeline through internal R&D and partnerships, aiming to solidify its position as a key player in global infectious disease therapeutics. Its operations span development, manufacturing, and commercialization, with a strong emphasis on markets in Asia and Africa.

Therapeutic Areas